Differential Disruption of EWS-FLI1 Binding by DNA-Binding Agents

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Chen, Changmin ^a   Wonsey, Diane R ^a   Lemieux, Madeleine E ^a,c   Kung, Andrew L ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c Bioinfo   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CISPLATIN; CLOFAZIMINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EBSELEN; EPIRUBICIN; ETHOXYQUIN; GENOMIC DNA; MEPACRINE; OMEPRAZOLE; PHENYLMERCURIC ACETATE; PROTEIN P53; PURVALANOL A; RNA BINDING PROTEIN EWS; SHIKONIN; TRANSCRIPTION FACTOR FLI 1; VERTEPORFIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SCREENING; EWING SARCOMA; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE TARGETING; HIGH THROUGHPUT SEQUENCING; HUMAN; IN VITRO STUDY; PROTEIN DNA BINDING; SARCOMA CELL; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATIN; DACTINOMYCIN; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING;

EID: 84880694067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069714     Document Type: Article

References (31)

1. Leavey PJ, Collier AB, (2008) Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 8: 617-624.
2. Ludwig JA, (2008) Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 20: 412-418.
3. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, et al. (2000) Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18: 3108-3114.
4. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, et al. (1993) Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 90: 5752-5756.
5. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. (1993) The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393-7398.
6. Im YH, Kim HT, Lee C, Poulin D, Welford S, et al. (2000) EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Cancer Res 60: 1536-1540.
7. Wang L, Bhargava R, Zheng T, Wexler L, Collins MH, et al. (2007) Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn 9: 498-509.
8. Kinsey M, Smith R, Lessnick SL, (2006) NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 4: 851-859.
9. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES, (1995) Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 11: 1049-1054.
10. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, et al. (2006) Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9: 405-416.
11. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, et al. (2011) Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13: 145-153.
12. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, et al. (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103: 962-978.
13. Raskatov JA, Meier JL, Puckett JW, Yang F, Ramakrishnan P, et al. (2012) Modulation of NF-kappaB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A 109: 1023-1028.
14. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG Jr, et al. (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 101: 16768-16773.
15. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, et al. (2008) Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A 105: 10149-10154.
16. Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, et al. (2012) Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res 22: 259-270.
17. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
18. Chen C, Shanmugasundaram K, Rigby AC, Kung AL, (2013) Shikonin, a natural product from the root of Lithospermum erythrorhizon, is a cytotoxic DNA-binding agent. European Journal of Pharmaceutical Sciences 49: 18-26.
19. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289-300.
20. Hollstein U, (1974) Actinomycin. Chemistry and mechanism of action. chemical reviews 74: 625-652.
21. Brown SC, Mullis K, Levenson C, Shafer RH, (1984) Aqueous solution structure of an intercalated actinomycin D-dATGCAT complex by two-dimensional and one-dimensional proton NMR. Biochemistry 23: 403-408.
22. Fox KR, Waring MJ, (1984) DNA structural variations produced by actinomycin and distamycin as revealed by DNAase I footprinting. Nucleic Acids Res 12: 9271-9285.
23. Goodisman J, Rehfuss R, Ward B, Dabrowiak JC, (1992) Site-specific binding constants for actinomycin D on DNA determined from footprinting studies. Biochemistry 31: 1046-1058.
24. Kamitori S, Takusagawa F, (1992) Crystal structure of the 2: 1 complex between d(GAAGCTTC) and the anticancer drug actinomycin D. J Mol Biol. 225: 445-456.
25. Krugh TR, Neely JW, (1973) Actinomycin D-deoxydinucleotide interactions as a model for binding of the drug to deoxyribonucleic acid. Proton magnetic resonance results. Biochemistry 12: 4418-4425.
26. Lane MJ, Dabrowiak JC, Vournakis JN, (1983) Sequence specificity of actinomycin D and Netropsin binding to pBR322 DNA analyzed by protection from DNase I. Proc Natl Acad Sci U S A. 80: 3260-3264.
27. Patel DJ, (1974) Peptide antibiotic-dinucleotide interactions. Nuclear magnetic resonance investigations of complex formation between actinomycin D and d-pGpC in aqueous solution. Biochemistry 13: 2388-2395.
28. Patel DJ, (1974) Peptide antibiotic-oligonucleotide interactions. Nuclear magnetic resonance investigations of complex formation between actinomycin D and d-ApTpGpCpApT in aqueous solution. Biochemistry 13: 2396-2402.
29. Krugh TR, Neely JW, (1973) Actinomycin D-mononucleotide interactions as studied by proton magnetic resonance. Biochemistry 12: 1775-1782.
30. Sobell HM, Jain SC, Sakore TD, Nordman CE, (1971) Stereochemistry of actinomycin-DNA binding. Nat New Biol 231: 200-205.
31. Bailey SA, Graves DE, Rill R, (1994) Binding of actinomycin D to the T(G)nT motif of double-stranded DNA: determination of the guanine requirement in nonclassical, non-GpC binding sites. Biochemistry 33: 11493-11500.